Vertex Pharmaceuticals Incorporated (0QZU.L)
USD 459.0
(-6.32%)
USD 459.0
(-6.32%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 724.7 Million USD | 53.67% |
| 2022 | 471.6 Million USD | -15.29% |
| 2021 | 556.7 Million USD | -4.26% |
| 2020 | 581.47 Million USD | 0.71% |
| 2019 | 577.37 Million USD | 1.8% |
| 2018 | 567.16 Million USD | 0.58% |
| 2017 | 563.91 Million USD | -32.73% |
| 2016 | 838.24 Million USD | 2.15% |
| 2015 | 820.61 Million USD | -0.57% |
| 2014 | 825.29 Million USD | 87.17% |
| 2013 | 440.93 Million USD | -34.45% |
| 2012 | 672.63 Million USD | 68.16% |
| 2011 | 400 Million USD | 0.0% |
| 2010 | 400 Million USD | 160.02% |
| 2009 | 153.83 Million USD | -46.49% |
| 2008 | 287.5 Million USD | 0.0% |
| 2007 | - USD | -100.0% |
| 2006 | 19.99 Million USD | -88.9% |
| 2005 | 180.09 Million USD | -46.24% |
| 2004 | 334.99 Million USD | -1.68% |
| 2003 | 340.72 Million USD | 4.54% |
| 2002 | 325.94 Million USD | 0.9% |
| 2001 | 323.02 Million USD | -6.99% |
| 2000 | 347.31 Million USD | 7289.64% |
| 1999 | 4.7 Million USD | -32.86% |
| 1998 | 7 Million USD | 18.64% |
| 1997 | 5.9 Million USD | 5.36% |
| 1996 | 5.6 Million USD | 14.29% |
| 1995 | 4.9 Million USD | 4.26% |
| 1994 | 4.7 Million USD | 11.9% |
| 1993 | 4.2 Million USD | 27.27% |
| 1992 | 3.3 Million USD | 57.14% |
| 1991 | 2.1 Million USD | -12.5% |
| 1990 | 2.4 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 721.3 Million USD | -0.47% |
| 2024 Q2 | 933.4 Million USD | 29.41% |
| 2024 Q3 | 1.7 Billion USD | -100.0% |
| 2023 Q1 | 789.2 Million USD | 67.35% |
| 2023 Q3 | 744.7 Million USD | -2.98% |
| 2023 FY | 724.7 Million USD | 53.67% |
| 2023 Q2 | 767.6 Million USD | -2.74% |
| 2023 Q4 | 724.7 Million USD | -2.69% |
| 2022 FY | 471.6 Million USD | -15.29% |
| 2022 Q2 | 531.6 Million USD | -2.32% |
| 2022 Q3 | 482 Million USD | -9.33% |
| 2022 Q4 | 471.6 Million USD | -2.16% |
| 2022 Q1 | 544.2 Million USD | -2.25% |
| 2021 Q2 | 569.75 Million USD | -0.54% |
| 2021 FY | 556.7 Million USD | -4.26% |
| 2021 Q1 | 572.85 Million USD | -1.48% |
| 2021 Q3 | 558.93 Million USD | -1.9% |
| 2021 Q4 | 556.7 Million USD | -0.4% |
| 2020 Q4 | 581.47 Million USD | -1.07% |
| 2020 Q2 | 562.47 Million USD | -1.82% |
| 2020 Q3 | 587.77 Million USD | 4.5% |
| 2020 FY | 581.47 Million USD | 0.71% |
| 2020 Q1 | 572.91 Million USD | -0.77% |
| 2019 Q1 | 596.1 Million USD | 5.1% |
| 2019 FY | 577.37 Million USD | 1.8% |
| 2019 Q4 | 577.37 Million USD | -0.22% |
| 2019 Q3 | 578.62 Million USD | -1.69% |
| 2019 Q2 | 588.57 Million USD | -1.26% |
| 2018 Q1 | 567.49 Million USD | 0.64% |
| 2018 Q4 | 567.16 Million USD | 0.25% |
| 2018 Q2 | 570.12 Million USD | 0.46% |
| 2018 Q3 | 565.74 Million USD | -0.77% |
| 2018 FY | 567.16 Million USD | 0.58% |
| 2017 Q2 | 525.54 Million USD | 5.26% |
| 2017 Q4 | 563.91 Million USD | 2.99% |
| 2017 FY | 563.91 Million USD | -32.73% |
| 2017 Q1 | 499.28 Million USD | -40.44% |
| 2017 Q3 | 547.54 Million USD | 4.19% |
| 2016 FY | 838.24 Million USD | 2.15% |
| 2016 Q3 | 815.74 Million USD | -0.65% |
| 2016 Q4 | 838.24 Million USD | 2.76% |
| 2016 Q2 | 821.09 Million USD | -0.47% |
| 2016 Q1 | 824.94 Million USD | 0.53% |
| 2015 Q3 | 820.98 Million USD | -0.42% |
| 2015 Q1 | 833.9 Million USD | 1.04% |
| 2015 Q2 | 824.46 Million USD | -1.13% |
| 2015 FY | 820.61 Million USD | -0.57% |
| 2015 Q4 | 820.61 Million USD | -0.04% |
| 2014 Q1 | 473.36 Million USD | 7.35% |
| 2014 Q3 | 767.91 Million USD | 62.26% |
| 2014 FY | 825.29 Million USD | 87.17% |
| 2014 Q4 | 825.29 Million USD | 7.47% |
| 2014 Q2 | 473.26 Million USD | -0.02% |
| 2013 Q4 | 440.93 Million USD | 12.32% |
| 2013 Q3 | 392.56 Million USD | 9.32% |
| 2013 Q2 | 359.1 Million USD | -49.9% |
| 2013 Q1 | 716.82 Million USD | 6.57% |
| 2013 FY | 440.93 Million USD | -34.45% |
| 2012 Q3 | 400 Million USD | 0.0% |
| 2012 FY | 672.63 Million USD | 68.16% |
| 2012 Q1 | 400 Million USD | 0.0% |
| 2012 Q4 | 672.63 Million USD | 68.16% |
| 2012 Q2 | 400 Million USD | 0.0% |
| 2011 Q2 | 400 Million USD | 0.0% |
| 2011 FY | 400 Million USD | 0.0% |
| 2011 Q4 | 400 Million USD | 0.0% |
| 2011 Q3 | 400 Million USD | 0.0% |
| 2011 Q1 | 400 Million USD | 0.0% |
| 2010 Q1 | 125.31 Million USD | 2.92% |
| 2010 FY | 400 Million USD | 160.02% |
| 2010 Q4 | 400 Million USD | 0.0% |
| 2010 Q3 | 400 Million USD | 362.93% |
| 2010 Q2 | 86.4 Million USD | -31.05% |
| 2009 FY | 153.83 Million USD | -46.49% |
| 2009 Q1 | 287.5 Million USD | 0.0% |
| 2009 Q2 | 144 Million USD | -49.91% |
| 2009 Q3 | 144 Million USD | 0.0% |
| 2009 Q4 | 121.76 Million USD | -15.44% |
| 2008 Q1 | 287.5 Million USD | 0.0% |
| 2008 Q2 | 287.5 Million USD | 0.0% |
| 2008 Q3 | 287.5 Million USD | 0.0% |
| 2008 Q4 | 287.5 Million USD | 0.0% |
| 2008 FY | 287.5 Million USD | 0.0% |
| 2007 Q1 | 19.99 Million USD | 0.0% |
| 2007 Q2 | - USD | -100.0% |
| 2007 FY | - USD | -100.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2006 Q1 | 180.09 Million USD | 0.0% |
| 2006 Q4 | 19.99 Million USD | -66.47% |
| 2006 Q2 | 180.09 Million USD | -0.0% |
| 2006 Q3 | 59.64 Million USD | -66.88% |
| 2006 FY | 19.99 Million USD | -88.9% |
| 2005 Q3 | 294.54 Million USD | -12.07% |
| 2005 Q4 | 180.09 Million USD | -38.86% |
| 2005 Q1 | 334.99 Million USD | 0.0% |
| 2005 FY | 180.09 Million USD | -46.24% |
| 2005 Q2 | 334.99 Million USD | 0.0% |
| 2004 Q4 | 334.99 Million USD | 6.35% |
| 2004 Q1 | 315 Million USD | -7.55% |
| 2004 Q2 | 317.92 Million USD | 0.93% |
| 2004 Q3 | 315 Million USD | -0.92% |
| 2004 FY | 334.99 Million USD | -1.68% |
| 2003 Q1 | 328.52 Million USD | 0.79% |
| 2003 FY | 340.72 Million USD | 4.54% |
| 2003 Q3 | 340.49 Million USD | 0.95% |
| 2003 Q4 | 340.72 Million USD | 0.07% |
| 2003 Q2 | 337.28 Million USD | 2.67% |
| 2002 Q3 | 321.31 Million USD | -0.13% |
| 2002 Q4 | 325.94 Million USD | 1.44% |
| 2002 Q2 | 321.73 Million USD | -0.19% |
| 2002 Q1 | 322.33 Million USD | -0.22% |
| 2002 FY | 325.94 Million USD | 0.9% |
| 2001 Q2 | 346.63 Million USD | -0.1% |
| 2001 Q3 | 354.18 Million USD | 2.18% |
| 2001 FY | 323.02 Million USD | -6.99% |
| 2001 Q4 | 323.02 Million USD | -8.8% |
| 2001 Q1 | 346.96 Million USD | -0.1% |
| 2000 Q4 | 347.31 Million USD | -0.23% |
| 2000 Q3 | 348.12 Million USD | 94.9% |
| 2000 Q2 | 178.61 Million USD | -0.3% |
| 2000 Q1 | 179.15 Million USD | 3711.81% |
| 2000 FY | 347.31 Million USD | 7289.64% |
| 1999 Q1 | 6.4 Million USD | -8.57% |
| 1999 Q2 | 5.8 Million USD | -9.38% |
| 1999 Q3 | 5.3 Million USD | -8.62% |
| 1999 Q4 | 4.7 Million USD | -11.32% |
| 1999 FY | 4.7 Million USD | -32.86% |
| 1998 Q2 | 6.9 Million USD | 11.29% |
| 1998 Q1 | 6.2 Million USD | 5.08% |
| 1998 Q3 | 7.6 Million USD | 10.14% |
| 1998 Q4 | 7 Million USD | -7.89% |
| 1998 FY | 7 Million USD | 18.64% |
| 1997 Q4 | 5.9 Million USD | 7.27% |
| 1997 Q2 | 5.4 Million USD | 1.89% |
| 1997 Q1 | 5.3 Million USD | -5.36% |
| 1997 FY | 5.9 Million USD | 5.36% |
| 1997 Q3 | 5.5 Million USD | 1.85% |
| 1996 Q1 | 4.4 Million USD | -10.2% |
| 1996 FY | 5.6 Million USD | 14.29% |
| 1996 Q3 | 4.4 Million USD | -4.35% |
| 1996 Q4 | 5.6 Million USD | 27.27% |
| 1996 Q2 | 4.6 Million USD | 4.55% |
| 1995 Q2 | 5.1 Million USD | 4.08% |
| 1995 Q3 | 4.9 Million USD | -3.92% |
| 1995 Q4 | 4.9 Million USD | 0.0% |
| 1995 FY | 4.9 Million USD | 4.26% |
| 1995 Q1 | 4.9 Million USD | 4.26% |
| 1994 FY | 4.7 Million USD | 11.9% |
| 1994 Q2 | 4.4 Million USD | 12.82% |
| 1994 Q3 | 4.7 Million USD | 6.82% |
| 1994 Q1 | 3.9 Million USD | -7.14% |
| 1994 Q4 | 4.7 Million USD | 0.0% |
| 1993 Q4 | 4.2 Million USD | 5.0% |
| 1993 Q1 | 3.4 Million USD | 3.03% |
| 1993 Q2 | 3.9 Million USD | 14.71% |
| 1993 FY | 4.2 Million USD | 27.27% |
| 1993 Q3 | 4 Million USD | 2.56% |
| 1992 Q2 | 2.9 Million USD | 26.09% |
| 1992 FY | 3.3 Million USD | 57.14% |
| 1992 Q1 | 2.3 Million USD | 9.52% |
| 1992 Q3 | 3.3 Million USD | 13.79% |
| 1992 Q4 | 3.3 Million USD | 0.0% |
| 1991 FY | 2.1 Million USD | -12.5% |
| 1991 Q2 | 2.5 Million USD | 0.0% |
| 1991 Q3 | 2.4 Million USD | -4.0% |
| 1991 Q4 | 2.1 Million USD | -12.5% |
| 1990 FY | 2.4 Million USD | 0.0% |
| 1990 Q4 | 2.4 Million USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| uniQure N.V. | 130.06 Million USD | -457.183% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -1171.671% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | -86.847% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | -1486.02% |
| bluebird bio, Inc. | 224.41 Million USD | -222.923% |
| Cara Therapeutics, Inc. | 37.07 Million USD | -1854.476% |
| Imunon, Inc. | 1.13 Million USD | -63509.625% |
| Editas Medicine, Inc. | 24.37 Million USD | -2873.494% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 94.406% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 63.317% |
| Myriad Genetics, Inc. | 130.9 Million USD | -453.629% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | -180.565% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -2083.094% |
| Verastem, Inc. | 40.08 Million USD | -1707.863% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 90.991% |
| Waters Corporation | 2.3 Billion USD | 68.567% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 97.685% |
| Biogen Inc. | 7.18 Billion USD | 89.918% |
| Nektar Therapeutics | 112.62 Million USD | -543.463% |
| Perrigo Company plc | 3.63 Billion USD | 80.051% |
| Dynavax Technologies Corporation | 252.41 Million USD | -187.103% |
| Illumina, Inc. | 1.48 Billion USD | 51.33% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -22276.739% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -72370.0% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -317.086% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -2978.72% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | -22.19% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -2062.315% |
| Evolus, Inc. | 120.35 Million USD | -502.115% |
| Adicet Bio, Inc. | 17.7 Million USD | -3993.656% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -23475.146% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 73.188% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | -44.493% |
| FibroGen, Inc. | 89.69 Million USD | -707.942% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 73.503% |
| OPKO Health, Inc. | 222.03 Million USD | -226.391% |
| Homology Medicines, Inc. | 43.17 Million USD | -1578.479% |
| Geron Corporation | 35.05 Million USD | -1967.559% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 69.07% |
| Exelixis, Inc. | 189.94 Million USD | -281.534% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -77325.214% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | -649.067% |
| Zoetis Inc. | 6.56 Billion USD | 88.959% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | -306.975% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -16362.971% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -2019.626% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 48.25% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 36.01% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 51.662% |
| Blueprint Medicines Corporation | 610.96 Million USD | -18.616% |
| Insmed Incorporated | 1.19 Billion USD | 39.272% |
| TG Therapeutics, Inc. | 100.11 Million USD | -623.846% |
| Incyte Corporation | 29.16 Million USD | -2385.083% |
| Emergent BioSolutions Inc. | 446.5 Million USD | -62.307% |